DRG Market Assessment reports

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…

Market Outlook: NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience…

Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the prevalence of the disease. The body of…

The high number of premium-priced NSCLC therapies and the large number of NSCLC patients result in significant financial burden for payers. These costs are set to increase with the approval of…

Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…

Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small…

MARKET OUTLOOK QUESTIONS ANSWERED What are the treatment drivers and goals for [[indication]]? What drug attributes are key influencers, which have limited impact, and which are hidden…

Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in indications such as…

Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…